|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-7-20
|
|
pubmed:abstractText |
Linagliptin (BI 1356) is a novel, orally available inhibitor of dipeptidyl peptidase-4 (DPP-4). Linagliptin improves glycaemic control in type 2 diabetic patients by increasing the half-life of the incretin hormone glucagon-like peptide-1 (GLP-1). Linagliptin is expected to be used as monotherapy or in combination with other antihyperglycaemic agents. This study was conducted to investigate potential pharmacokinetic or pharmacodynamic interactions between linagliptin and metformin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1473-4877
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1963-72
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19552619-Adult,
pubmed-meshheading:19552619-Cross-Over Studies,
pubmed-meshheading:19552619-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:19552619-Dose-Response Relationship, Drug,
pubmed-meshheading:19552619-Drug Interactions,
pubmed-meshheading:19552619-Humans,
pubmed-meshheading:19552619-Hypoglycemic Agents,
pubmed-meshheading:19552619-Male,
pubmed-meshheading:19552619-Metformin,
pubmed-meshheading:19552619-Middle Aged,
pubmed-meshheading:19552619-Purines,
pubmed-meshheading:19552619-Quinazolines,
pubmed-meshheading:19552619-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
|
|
pubmed:affiliation |
Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, D-88397 Biberach/Riss, Germany. EvaUlrike.Graefe-Mody@boehringer-ingelheim.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
